Evidence map›Paper›PMID 38464735›Full record

ArticleFrontiers in ophthalmology2023

The endothelin receptor antagonist macitentan ameliorates endothelin-mediated vasoconstriction and promotes the survival of retinal ganglion cells in rats.

Bindu Kodati, Wei Zhang, Shaoqing He, Jennifer H Pham, Kallen J Beall, Zoe E Swanger, Vignesh R Krishnamoorthy, Payton E Harris, Trent Hall, Ashley V Tran and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Frontiers in ophthalmology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The impact of matrix metalloproteinases and their tissue inhibitors in patients with chronic glaucoma - a literature review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 10 institutions in 1 country.

Bindu KodatiDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States.
Wei ZhangDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States.
Shaoqing HeDepartment of Pathology, Children's Health at Dallas, Dallas, TX, United States.
Jennifer H PhamDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States.
Kallen J BeallDepartment of General Surgery, Honor Health, Phoenix, AZ, United States.
Zoe E SwangerTexas College of Osteopathic Medicine, University of North Texas Health Science Center, Fort Worth, TX, United States.
Vignesh R KrishnamoorthyDepartment of Cell and Molecular Pharmacology, Loyola University, Maywood, IL, United States.
Payton E HarrisDepartment of Graduate Medical Education, Medical City, Fort Worth, TX, United States.
Trent HallWilliams College, Williamstown, MA, United States.
Ashley V TranSchool of Natural Sciences and Mathematics, The University of Texas at Dallas, Richardson, TX, United States.
Renuka M ChaphalkarDepartment of Ophthalmology, School of Medicine, University of California, San Francisco, CA, United States.
Sai H ChavalaDepartment of Surgery, Burnett School of Medicine at Texas Christian University (TCU), Fort Worth, TX, United States.
Dorota L StankowskaDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States.
Raghu R KrishnamoorthyDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, United States.
University of North Texas Health Science Center · USSmith-Kettlewell Eye Research Institute · USHonorHealth · USLoyola University Chicago · USTexas Christian University · USThe University of Texas at Dallas · USUniversity of California, San Francisco · USUniversity of North Texas · USUniversity of Texas Health Science Center at Dallas · USWilliams College · US

Funding

Mechanisms underlying endothelin mediated neurodegeneration in glaucomaR01EY028179 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI KRISHNAMOORTHY, RAGHU R · 2017 to 2025
$2.9M
NEI NIH HHS R01 EY028179
6 · The paper itself

Abstract

Glaucoma is a chronic and progressive eye disease, commonly associated with elevated intraocular pressure (IOP) and characterized by optic nerve degeneration, cupping of the optic disc, and loss of retinal ganglion cells (RGCs). The pathological changes in glaucoma are triggered by multiple mechanisms and both mechanical effects and vascular factors are thought to contribute to the etiology of glaucoma. Various studies have shown that endothelin-1 (ET-1), a vasoactive peptide, acting through its G protein coupled receptors, ET

Indexed as

endothelinsglaucomamacitentanneuroprotectionvasoconstriction

Identifiers

PMID38464735
PMCPMC10921982
OpenAlexW4380878442

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.